RESUMEN
@#Adenoid cystic carcinoma of lacrimal gland(LGACC)is the most common malignant epithelial tumor of the lacrimal gland, which is characterized by high recurrence rate, easy metastasis and poor prognosis. Although the current clinical treatment modalities for adenoid cystic carcinoma of lacrimal gland mainly include surgical resection, radiotherapy, and chemotherapy, its survival rate is still low. Therefore, it is particularly urgent to further study the pathogenesis of adenoid cystic carcinoma of the lacrimal gland and find out the biomarkers for adenoid cystic carcinoma of the lacrimal gland. In this paper, we will review the research progress in biomarkers of adenoid cystic carcinoma of the lacrimal gland.
RESUMEN
@#Adenoid cystic carcinoma of lacrimal gland is the most common malignant epithelial tumor of the lacrimal gland, and surgical treatment alone shows unsatisfactory result. In recent years, as the application of radiotherapy and chemotherapy, changes have happened in the treatment modality for adenoid cystic carcinoma of lacrimal gland. On one hand, clinical staging is gradually refined, which promote the application of standardized comprehensive treatment. On the other hand, neoadjuvant therapies, such as proton radiotherapy, neutron radiotherapy and intra-arterial cytoreductive chemotherapy, can further improve the application of eye-sparing surgery, decrease the rate of local recurrence and metastasis, and prolong the disease-free survival. In this review, we attempt to arrive at some general insights regarding the progress of treatment in adenoid cystic carcinoma of lacrimal gland, in order to provide new reference basis.